{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:45:07Z","timestamp":1792032307269,"version":"4.4.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.steroids.2006.10.009","type":"journal-article","created":{"date-parts":[[2006,12,14]],"date-time":"2006-12-14T12:10:44Z","timestamp":1166098244000},"page":"7-25","source":"Crossref","is-referenced-by-count":235,"title":["Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer"],"prefix":"10.1016","volume":"72","author":[{"given":"V. Craig","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.H.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2006.10.009_bib1","unstructured":"Hoagland H. The road to yesterday. Worcester MA; 1974."},{"key":"10.1016\/j.steroids.2006.10.009_bib2","first-page":"387","article-title":"Basic guides to the mechanism of estrogen action","volume":"18","author":"Jensen","year":"1962","journal-title":"Recent Prog Hormone Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/1097-0142(196512)18:12<1551::AID-CNCR2820181206>3.0.CO;2-1","article-title":"Hormone therapy for advanced breast cancer","volume":"18","author":"Kennedy","year":"1965","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib4","first-page":"55","article-title":"Estrogen receptors and breast cancer response to adrenalectomy","volume":"34","author":"Jensen","year":"1971","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.steroids.2006.10.009_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474","volume":"25","author":"Cole","year":"1971","journal-title":"Br J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/jrf.0.0130101","article-title":"A new derivative of triphenylethylene: effect on implantation and mode of action in rats","volume":"13","author":"Harper","year":"1967","journal-title":"J Reprod Fertil"},{"key":"10.1016\/j.steroids.2006.10.009_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1677\/joe.0.0370083","article-title":"Mode of action of I.C.I. 46,474 in preventing implantation in rats","volume":"37","author":"Harper","year":"1967","journal-title":"J Endocrinol"},{"key":"10.1016\/j.steroids.2006.10.009_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF01807278","article-title":"The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole","volume":"11","author":"Jordan","year":"1988","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2006.10.009_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/189204a0","article-title":"Mammary cancer induced by a single feeding of polynuclear hydrocarbons and their suppression","volume":"189","author":"Huggins","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2006.10.009_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2964(75)90119-X","article-title":"(ICI 46,474) and the human carcinoma 8S oestrogen receptor","volume":"11","author":"Jordan","year":"1975","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib11","series-title":"Proceedings Eastern Cooperative Oncology Group Meeting","article-title":"The antioestrogen tamoxifen (ICI 46,474) as an antitumour agent","author":"Jordan","year":"1974"},{"key":"10.1016\/j.steroids.2006.10.009_bib12","first-page":"1409","article-title":"Antiestrogenic and antitumor properties of tamoxifen in laboratory animals","volume":"60","author":"Jordan","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.steroids.2006.10.009_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.steroids.2006.10.009_bib14","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1038\/sj.bjp.0706399","article-title":"(ICI 46,474) as a targeted therapy to treat and prevent breast cancer","volume":"147","author":"Jordan","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.steroids.2006.10.009_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1677\/joe.0.0680297","article-title":"Tamoxifen as an anti-tumour agent: effect on oestrogen binding","volume":"68","author":"Jordan","year":"1976","journal-title":"J Endocrinol"},{"key":"10.1016\/j.steroids.2006.10.009_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.0680453","article-title":"Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response","volume":"68","author":"Jordan","year":"1976","journal-title":"J Endocrinol"},{"key":"10.1016\/j.steroids.2006.10.009_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2964(76)90030-X","article-title":"Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma","volume":"12","author":"Jordan","year":"1976","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib18","first-page":"49","article-title":"Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy","author":"Jordan","year":"1978","journal-title":"Rev Endocr Relat Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib19","first-page":"19","article-title":"The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer","volume":"2","author":"Jordan","year":"1979","journal-title":"Adj Ther Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2964(80)90156-5","article-title":"Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model","volume":"16","author":"Jordan","year":"1980","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01806042","article-title":"Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study","volume":"4","author":"Tormey","year":"1984","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2006.10.009_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01807370","article-title":"Long-term adjuvant tamoxifen study: clinical update","volume":"9","author":"Tormey","year":"1987","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2006.10.009_bib23","first-page":"1205","article-title":"Review of mortality results in randomized trials in early breast cancer","volume":"ii","author":"Anonymous","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib24","unstructured":"EBCTCG. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319:1681\u201392."},{"key":"10.1016\/j.steroids.2006.10.009_bib25","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1001\/jama.254.24.3461","article-title":"Adjuvant chemotherapy for breast cancer","volume":"254","year":"1985","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.steroids.2006.10.009_bib26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1210\/endo-92-3-866","article-title":"Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta","volume":"92","author":"Schwarzel","year":"1973","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2006.10.009_bib27","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1210\/endo-100-6-1684","article-title":"The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen dependent processes in reproduction and breast cancer","volume":"100","author":"Brodie","year":"1977","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2006.10.009_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0039-128X(81)90087-8","article-title":"Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3, 17-dione and sustained effects in vivo","volume":"38","author":"Brodie","year":"1981","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2006.10.009_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1210\/endo-106-1-19","article-title":"Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione","volume":"106","author":"Brodie","year":"1980","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2006.10.009_bib30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1210\/jcem-45-3-480","article-title":"Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels","volume":"45","author":"Samojlik","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.steroids.2006.10.009_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1097-0142(197402)33:2<503::AID-CNCR2820330227>3.0.CO;2-L","article-title":"Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer","volume":"33","author":"Lipton","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198109033051003","article-title":"A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer","volume":"305","author":"Santen","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2006.10.009_bib33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/1097-0142(19800815)46:4+<1066::AID-CNCR2820461335>3.0.CO;2-M","article-title":"The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast","volume":"46","author":"Santen","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib34","first-page":"1980","article-title":"The estrogen receptor: a model for molecular medicine. The Dorothy P. Landon AACR Prize for Translational Research","volume":"9","author":"Jensen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jcem-73-4-717","article-title":"Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study","volume":"73","author":"Inkster","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.steroids.2006.10.009_bib36","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1126\/science.6163211","article-title":"Sexual differentiation of the central nervous system","volume":"211","author":"MacClusky","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.steroids.2006.10.009_bib37","doi-asserted-by":"crossref","unstructured":"Balthazart, J, Steroid metabolism and the activation of social behavior. In: Balthazart J, editor. Advances in comparative and environmental physiology, vol. 3. Germany, Berlin: Springer; 1989. p. 105\u20139.","DOI":"10.1007\/978-3-642-73827-2_3"},{"key":"10.1016\/j.steroids.2006.10.009_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1210\/jcem-46-1-146","article-title":"Aromatization of androgens by muscle and adipose tissue in vivo","volume":"46","author":"Longcope","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.steroids.2006.10.009_bib39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jcem-38-3-476","article-title":"Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age","volume":"38","author":"Hemsell","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.steroids.2006.10.009_bib40","first-page":"2900","article-title":"Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue","volume":"45","author":"van Landeghem","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09513599209081001","article-title":"Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons","volume":"6","author":"Blankenstein","year":"1992","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.steroids.2006.10.009_bib42","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1021\/bi00318a004","article-title":"Hydroperoxides as inactivators of aromatase: 10 beta-hydroperoxy-4-estrene-3,17-dione, crystal structure and inactivation characteristics","volume":"23","author":"Covey","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.steroids.2006.10.009_bib43","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0021-9258(17)43462-4","article-title":"Immunological probe of estrogen biosynthesis. Evidence for the 2 beta-hydroxylative pathway in aromatization of androgens","volume":"259","author":"Hahn","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.steroids.2006.10.009_bib44","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.87.8.2999","article-title":"Conversion of a 3-desoxysteroid to 3-desoxyestrogen by human placental aromatase","volume":"87","author":"Cole","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.steroids.2006.10.009_bib45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1432-1033.2001.01886.x","article-title":"Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study","volume":"268","author":"Kao","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.steroids.2006.10.009_bib46","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1021\/ja044716w","article-title":"The final catalytic step of cytochrome p450 aromatase: a density functional theory study","volume":"127","author":"Hackett","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.steroids.2006.10.009_bib47","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/0006-2952(82)90415-4","article-title":"The effect of 1,4,6-androstatriene-3,17-dione (ATD) on DMBA-induced mammary tumors in the rat and its mechanism of action in vivo","volume":"31","author":"Brodie","year":"1982","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.steroids.2006.10.009_bib48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0022-4731(76)90180-1","article-title":"Studies on the mechanism of estrogen biosynthesis in the rat ovary-1","volume":"7","author":"Brodie","year":"1976","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.steroids.2006.10.009_bib49","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0022-4731(79)90330-3","article-title":"Aromatase inhibitors IV. Regression of estrogen-dependent mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione","volume":"10","author":"Brodie","year":"1979","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.steroids.2006.10.009_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/clpt.1981.121","article-title":"Suicide inhibitors as potential drugs","volume":"30","author":"Sjoerdsma","year":"1981","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.steroids.2006.10.009_bib51","doi-asserted-by":"crossref","unstructured":"Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 2006; in press.","DOI":"10.1210\/me.2006-0281"},{"key":"10.1016\/j.steroids.2006.10.009_bib52","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/prot.20829","article-title":"Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes","volume":"62","author":"Favia","year":"2006","journal-title":"Proteins"},{"key":"10.1016\/j.steroids.2006.10.009_bib53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0039-128X(83)90069-7","article-title":"7\u03b1-Substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase","volume":"50","author":"Brueggemeier","year":"1987","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2006.10.009_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0960-0760(90)90488-7","article-title":"Biochemical pharmacology of new 7-substituted androstenediones as inhibitors of aromatase","volume":"37","author":"Brueggemeier","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0022-4731(86)90069-5","article-title":"1-Methyl-1,4-androstadiene-3, 17-dione (SH 489):Characterization of an irreversible inhibitor of estrogen biosynthesis","volume":"24","author":"Henderson","year":"1986","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib56","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1021\/ja00401a054","article-title":"Substrate-induced inactivation of aromatase by allenic and acetylenic steroids","volume":"103","author":"Metcalf","year":"1981","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.steroids.2006.10.009_bib57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/0277-5379(91)90313-3","article-title":"Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL-18962 in rats with DMBA-induced mammary tumors","volume":"27","author":"Zaccheo","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib58","first-page":"5933","article-title":"Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women","volume":"52","author":"Evans","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0959-8049(96)00494-7","article-title":"The minimal effective exemestane dose for endocrine activity in advanced breast cancer","volume":"33","author":"Bajetta","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib60","first-page":"29","article-title":"In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients","volume":"4","author":"Geisler","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib61","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.2000.18.11.2234","article-title":"Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial","volume":"18","author":"Lonning","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0076-6879(78)52029-6","article-title":"Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy","volume":"52","author":"Jefcoate","year":"1978","journal-title":"Meth Enzymol"},{"key":"10.1016\/j.steroids.2006.10.009_bib63","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1016\/S0021-9258(18)34823-3","article-title":"Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme","volume":"257","author":"Dawson","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1016\/j.steroids.2006.10.009_bib64","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem-27-9-1239","article-title":"Aminoglutethimide (Elipten-CIBA) as an inhibitor of adrenal steroidogenesis. Mechanism of action and therapeutic trial","volume":"27","author":"Cash","year":"1967","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.steroids.2006.10.009_bib65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0960-0760(93)90235-O","article-title":"Tissue-specific promoters regulate aromatase cytochrome P450 expression","volume":"44","author":"Simpson","year":"1993","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0960-0760(97)80013-1","article-title":"Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture","volume":"61","author":"Zhao","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.physiol.64.081601.142703","article-title":"Aromatase\u2014a brief overview","volume":"64","author":"Simpson","year":"2002","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.steroids.2006.10.009_bib68","doi-asserted-by":"crossref","first-page":"11762","DOI":"10.1158\/0008-5472.CAN-05-2792","article-title":"Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy","volume":"65","author":"Safi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib69","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/jm051126f","article-title":"Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition","volume":"49","author":"Su","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.steroids.2006.10.009_bib70","first-page":"5683","article-title":"Selective estrogen receptor modulation: a personal perspective","volume":"61","author":"Jordan","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/er.2003-0023","article-title":"Coregulator function: a key to understanding tissue specificity of selective receptor modulators","volume":"25","author":"Smith","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.steroids.2006.10.009_bib72","first-page":"3867","article-title":"A potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0969-2126(01)00568-8","article-title":"Structural insights into the mode of action of a pure antiestrogen","volume":"9","author":"Pike","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.steroids.2006.10.009_bib74","doi-asserted-by":"crossref","first-page":"35684","DOI":"10.1074\/jbc.M101097200","article-title":"The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators","volume":"276","author":"Wijayaratne","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.steroids.2006.10.009_bib75","first-page":"1","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women","volume":"339","author":"EBCTCG","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib76","first-page":"1451","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"354","author":"EBCTCG","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib77","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"EBCTCG","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib78","first-page":"1026","article-title":"Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen","volume":"48","author":"Ravdin","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib79","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/jnci\/83.20.1488","article-title":"Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent","volume":"83","author":"Jordan","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib80","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1200\/JCO.2005.03.0783","article-title":"Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93","volume":"24","author":"Colleoni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib82","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0960-9776(93)90119-Z","article-title":"Randomized trial of the selective aromatase inhibitor formestane (Lentaron) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer","volume":"3","author":"Perez-Carrion","year":"1993","journal-title":"Breast"},{"key":"10.1016\/j.steroids.2006.10.009_bib83","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0960-0760(93)90283-3","article-title":"The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer","volume":"44","author":"Demers","year":"1993","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib84","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib85","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib86","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib87","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib88","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","article-title":"Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer","volume":"14","author":"Paridaens","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib89","first-page":"22","article-title":"First-line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)\u2014a randomized phase III trial of the EORTC Group","author":"Paridaens","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib90","first-page":"460S","article-title":"Endocrine therapy of advanced disease: analysis and implications of the existing data","volume":"9","author":"Pritchard","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib91","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0960-0760(99)00051-5","article-title":"Aromatase and its inhibitors","volume":"69","author":"Brodie","year":"1999","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1677\/erc.0.0060075","article-title":"Use of aromatase inhibitors in breast carcinoma","volume":"6","author":"Santen","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib93","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djh076","article-title":"Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model","volume":"96","author":"Long","year":"2004","journal-title":"JNCI"},{"key":"10.1016\/j.steroids.2006.10.009_bib94","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2006.10.009_bib96","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2006.10.009_bib97","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004","volume":"23","author":"Winer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib98","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib99","first-page":"28","article-title":"Aromatase inhibition and antiestrogen therapy in early breast cancer treatmen and chemoprevention","volume":"15","author":"Ingle","year":"2001","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.steroids.2006.10.009_bib100","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdi158","article-title":"The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)","volume":"16","author":"Wasan","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib101","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"BIG (Breast International Group) and Group, I-C. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2006.10.009_bib102","first-page":"245","article-title":"Biochemical pharmacology of antiestrogen action","volume":"36","author":"Jordan","year":"1984","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.steroids.2006.10.009_bib103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","article-title":"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity","volume":"75","author":"Jordan","year":"1977","journal-title":"J Endocrinol"},{"key":"10.1016\/j.steroids.2006.10.009_bib104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1980.tb10912.x","article-title":"Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships","volume":"71","author":"Allen","year":"1980","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.steroids.2006.10.009_bib105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02405304","article-title":"Clomiphene protects against osteoporosis in the mature ovariectomized rat","volume":"36","author":"Beall","year":"1985","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.steroids.2006.10.009_bib106","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","article-title":"Effects of anti-estrogens on bone in castrated and intact female rats","volume":"10","author":"Jordan","year":"1987","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2006.10.009_bib107","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jbmr.5650020513","article-title":"Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats","volume":"2","author":"Turner","year":"1987","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib108","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1210\/endo-122-3-1146","article-title":"Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats","volume":"122","author":"Turner","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2006.10.009_bib109","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/81.14.1086","article-title":"Effects of tamoxifen on spinal bone density in women with breast cancer","volume":"81","author":"Turken","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2006.10.009_bib111","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","article-title":"Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer","volume":"82","author":"Love","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib112","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-115-11-860","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women","volume":"115","author":"Love","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.steroids.2006.10.009_bib113","first-page":"812","article-title":"Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib114","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(88)92675-X","article-title":"Tamoxifen as risk factor for carcinoma of corpus uterus","volume":"ii","author":"Hardell","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib115","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(88)90765-9","article-title":"Tamoxifen and endometrial cancer [letter]","volume":"2","author":"Jordan","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib116","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","article-title":"Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers","volume":"1","author":"Fornander","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib117","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(89)91741-8","article-title":"Tamoxifen and the uterus and endometrium","author":"Neven","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib118","first-page":"375","article-title":"Tamoxifen and the uterus and endometrium","volume":"i","author":"Stewart","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib119","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [see comments]","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","article-title":"High grade endometrial carcinoma in tamoxifen treated breast cancer patients","volume":"11","author":"Magriples","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2006.10.009_bib121","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib122","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib123","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000226637","article-title":"Phase II evaluation of Ly156758 in metastatic breast cancer","volume":"45","author":"Buzdar","year":"1988","journal-title":"Oncology"},{"key":"10.1016\/j.steroids.2006.10.009_bib124","first-page":"4020","article-title":"Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model","volume":"47","author":"Gottardis","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/07357908809082124","article-title":"Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations","volume":"6","author":"Jordan","year":"1988","journal-title":"Cancer Invest"},{"key":"10.1016\/j.steroids.2006.10.009_bib126","first-page":"4177","article-title":"The development of antiestrogens for the treatment of breast cancer: Eighth Cain Memorial Award Lecture","volume":"50","author":"Lerner","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib127","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0024-3205(83)90935-9","article-title":"Antagonism of estrogen action with a new benzothiophene derived antiestrogen","volume":"32","author":"Black","year":"1983","journal-title":"Life Sci"},{"key":"10.1016\/j.steroids.2006.10.009_bib128","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/endo-113-2-463","article-title":"Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018","volume":"113","author":"Jordan","year":"1983","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2006.10.009_bib129","first-page":"3189","article-title":"Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice","volume":"50","author":"Gottardis","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib130","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [see comments] [published erratum appears in JAMA 1999 Dec 8;282(22):2124]","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2006.10.009_bib131","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. multiple outcomes of raloxifene evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2006.10.009_bib132","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2006.10.009_bib133","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"The study of tamoxifen and raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2006.10.009_bib134","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women","volume":"279","author":"Walsh","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2006.10.009_bib135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2006.10.009_bib136","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/jm020450x","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents","volume":"46","author":"Jordan","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.steroids.2006.10.009_bib137","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/156802606776173474","article-title":"Estrogen receptors as therapeutic targets in breast cancer","volume":"6","author":"Ariazi","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.steroids.2006.10.009_bib138","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2006.10.009_bib139","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0960-0760(03)00378-9","article-title":"Breast cancer prevention\u2014clinical trials strategies involving aromatase inhibitors","volume":"86","author":"Goss","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib140","first-page":"63","article-title":"Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention","volume":"1766","author":"Cavalieri","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.steroids.2006.10.009_bib141","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1096\/fj.05-5399com","article-title":"17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells","volume":"20","author":"Russo","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.steroids.2006.10.009_bib142","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-04-4502","article-title":"Activation of MAPK in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole","volume":"65","author":"Jelovac","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib143","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-04-2782","article-title":"Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model","volume":"65","author":"Jelovac","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib144","first-page":"2321","article-title":"Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines","volume":"56","author":"Pink","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib145","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/0277-5379(87)90062-9","article-title":"Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture","volume":"232","author":"Welshons","year":"1987","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib146","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0303-7207(92)90104-E","article-title":"An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol","volume":"90","author":"Jiang","year":"1992","journal-title":"Mol Cell Endocr"},{"key":"10.1016\/j.steroids.2006.10.009_bib147","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bjc.1996.521","article-title":"Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation","volume":"74","author":"Pink","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.steroids.2006.10.009_bib148","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(04)00059-5","article-title":"Selective estrogen receptor modulation: concept and consequences in cancer","volume":"5","author":"Jordan","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.steroids.2006.10.009_bib149","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jsbmb.2004.12.032","article-title":"Estrogen induced apoptosis in breast cancer model resistant to long-term estrogen withdrawal","volume":"94","author":"Lewis","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2006.10.009_bib150","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/jnci\/dji400","article-title":"Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation","volume":"97","author":"Lewis","year":"2005","journal-title":"JNCI"},{"key":"10.1016\/j.steroids.2006.10.009_bib151","first-page":"2028","article-title":"Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice","volume":"6","author":"Yao","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2006.10.009_bib152","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jnci\/djg080","article-title":"Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo","volume":"95","author":"Liu","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib153","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jnci\/djg079","article-title":"Paradoxical action of fulvestrant on estradiol-induced regression of tamoxifen-stimulated breast cancer","volume":"95","author":"Osipo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2006.10.009_bib154","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1010619225209","article-title":"High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy","volume":"67","author":"Lonning","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2006.10.009_bib155","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.breast.2005.08.022","article-title":"The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy","volume":"14","author":"Jordan","year":"2005","journal-title":"Breast"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X06002200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X06002200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T01:24:32Z","timestamp":1628213072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X06002200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0039128X06002200"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2006.10.009","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}